Correction:  BRAF V600E  -mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

M. Herman Chui; Susanne K. Kjaer; Kirsten Frederiksen; Charlotte G. Hannibal; Tian-Li Wang; Russell Vang; Ie-Ming Shih

doi:10.18632/oncotarget.28001

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: BRAF^V600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

PDF | How to cite

Oncotarget. 2021; 12:1323-1324. https://doi.org/10.18632/oncotarget.28001

Metrics: PDF 864 views | ?

M. Herman Chui¹, Susanne K. Kjaer^3,4, Kirsten Frederiksen³, Charlotte G. Hannibal³, Tian-Li Wang¹, Russell Vang^1,2,* and Ie-Ming Shih^1,2,*

¹ Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
² Department of Obstetrics & Gynecology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
³ Unit of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
⁴ Gynecologic Clinic, Juliane Marie Centre, Copenhagen University Hospital, Copenhagen, Denmark
^* These authors have contributed equally to this work

Published: June 22, 2021

Copyright: © 2021 Chui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Table 2, the numbers in column 2, rows 2 and 3, were accidentally switched. The corrected Table 2 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2019; 10:6870–6878. DOI: https://doi.org/10.18632/oncotarget.27326.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28001

Publication Alerts

Corrections:

Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma

Correction: BRAF^V600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma